Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …

Purpose We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in
Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term …

Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if
treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 …

The dramatic success of tyrosine kinase inhibitors (TKIs) has led to the widespread
perception that chronic myeloid leukemia (CML) has become another chronic disease …

Immunotherapy is known to be clinically beneficial for cancer patients and in many cases
represents the new standard of care. Because of this success, the interest in integrating …

Cancer drug resistance continues to be a major impediment in medical oncology. Clinically,
resistance can arise prior to or as a result of cancer therapy. In this review, we discuss …

Background Imatinib treatment significantly improves survival in patients with chronic
myeloid leukaemia (CML), but little is known about whether treatment can safely be …

Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …